RPL26L1

Across TCGA pan-cancer cohorts, RPL26L1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL26L1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RPL26L1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RPL26L1 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, COAD, and PDAC are the cancer types where RPL26L1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL26L1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.302	<.001	11	view →
COAD	Male	III,IV	+0.595	<.001	9	view →
PDAC	Male	All	−0.904	<.001	6	view →
LUAD	All	All	+0.262	<.001	5	view →
OV	All	All	+0.516	.038	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPL26L1–CCRCC

Open the CCRCC breakdown →